Related by context. All words. (Click for frequent words.) 71 ENMD # 71 Azedra 70 OMP #M# 70 oral prodrug 70 cancer immunotherapies 70 alvespimycin 70 DXL# 69 GLP toxicology studies 69 PhG alpha 1 69 preclinically 69 HGS ETR1 68 CR# vcMMAE 68 CBLC# 68 XmAb# 68 Onconase 68 PEG SN# 68 PSMA ADC 68 favorable pharmacokinetic profile 68 Panzem R NCD 68 drug GAP #B# 67 ATL# [001] 67 OncoVEX 67 PKCi 67 INCB# [001] 67 ESBA# 67 HGS ETR2 67 GRNVAC1 67 histone deacetylase inhibitor 67 CCX# 67 PXD# 67 Panzem 67 siRNA therapeutics 67 ganetespib 67 Sym# 67 Phase Ib study 66 humanized antibody 66 Virulizin ® 66 triphendiol 66 OXi# 66 Nanobody ® 66 Tarvacin TM 66 Angiolix 66 NEUGENE 66 CEQ# 66 indibulin 66 huC# DM4 66 CA4P 66 tubulin inhibitor 66 #ME# 66 CCR2 66 Ceflatonin 66 A3 adenosine receptor 66 Preclinical studies suggest 66 ProLindac 66 CORT # 66 Solazed 65 prostone 65 PCK# 65 SERMs 65 IMA# 65 HGS# 65 novel peptide 65 Aplidin 65 investigational therapies 65 ARIKACE ™ 65 Nanobody 65 liposomal formulation 65 AP# [003] 65 IMC A# 65 nonclinical studies 65 Cloretazine ® 65 CYC# 65 enzastaurin 65 Xanafide 65 JAK inhibitors 65 vascular disrupting agents 65 milatuzumab 65 molecular biomarkers 65 S/GSK# 65 HDAC inhibition 65 targeting CD# 65 AEG# 65 olaparib 65 BNC# 65 tanespimycin 65 vidofludimus 65 DACH platinum 65 NS#/#A protease 65 Archexin 65 neuroprotective properties 65 PI3K inhibitors 65 adenoviral 65 MAbs 65 nanoviricides 65 NXL# 65 anticancer compound 65 talabostat 65 Tyrima 65 therapeutic monoclonal antibody 65 ELACYT 65 CDK inhibitor 65 MET amplification 65 potent anticancer 65 AMPK activators 65 JAK2 inhibitor 65 Tarvacin 65 Zybrestat 65 CRD5 65 antiproliferative effects 65 Exherin TM 65 vivo potency 65 orally bioavailable 65 EndoTAG TM -1 65 Phase #b/#a clinical 65 VNP#M 65 molecularly targeted 65 mertansine 65 obatoclax 64 AKT inhibitor 64 MEK inhibitors 64 depsipeptide 64 tezampanel 64 Darinaparsin 64 alkylating agent 64 Symadex 64 mapatumumab 64 isoform selective 64 ALN VSP 64 lapatinib Tykerb 64 eniluracil 64 mTOR inhibition 64 rxRNA 64 OncoVEX GM CSF 64 thymalfasin 64 RNA antagonist 64 FOLOTYN ® 64 MGd 64 HuLuc# 64 CCR9 64 small molecule agonists 64 OvaRex R 64 CLORETAZINE TM VNP#M 64 CYT# potent vascular disrupting 64 investigational humanized monoclonal antibody 64 Anticalins ® 64 cMET 64 pharmacodynamic markers 64 antisense inhibitors 64 pomalidomide 64 OMAPRO 64 Enhanze Technology 64 Cotara 64 oral picoplatin 64 pharmacodynamic effects 64 Aurora kinase 64 rBChE 64 chemopreventive agent 64 REP# 64 OHR/AVR# 64 forodesine 64 Amplimexon 64 Seliciclib 64 busulfan 64 potent antiproliferative 64 TPI ASM8 64 Panzem NCD 64 Relivar 64 PNT# 64 LentiVector technology 64 Curaxin CBLC# 64 GLYX 64 therapeutic monoclonal antibodies 64 pertuzumab 64 YONDELIS 64 IMGN# 64 immune modulating 64 AQ4N 64 Abiraterone acetate 64 anticancer therapeutics 64 REOLYSIN ® 64 MOZOBIL 64 antiangiogenic activity 64 Squalamine 64 GMX# 64 Panzem R 64 BioVant 64 darinaparsin 64 GRN#L 64 Bezielle 64 HSP# inhibitor 64 Marqibo TM 64 EZN 64 theranostic 64 eTag assays 63 DAVANAT 63 mGluR2 NAM 63 antitumor effects 63 FGFR 63 CCR9 antagonist 63 omega interferon 63 tiapamil 63 non nucleoside 63 PI3K/Akt pathway inhibitor 63 BiTE 63 TLR9 agonists 63 synthetic retinoid 63 JAK3 63 romidepsin 63 BRAF inhibitors 63 Tesmilifene 63 vascular disrupting agent 63 oncolytic virus 63 Trofex TM 63 biomarker validation 63 trastuzumab DM1 T DM1 63 silico prediction 63 PDE4 inhibitor 63 HCV replicon 63 BrachySil 63 GRN# 63 SAR# [004] 63 BZL# 63 Insegia 63 radiation sensitizer 63 PANVAC VF 63 vivo validation 63 radiotherapeutic 63 microRNA biomarkers 63 systemically administered 63 JAK inhibitor 63 receptor tyrosine kinase inhibitor 63 orally dosed 63 CTAP# Capsules 63 vascular disrupting 63 MAGE A3 ASCI 63 deforolimus 63 AVE# 63 PSN# [002] 63 ASONEP 63 preclinical studies 63 preclinical 63 velafermin belinostat 63 TLR agonists 63 compound AEZS 63 radiolabeled 63 novel anticancer 63 liposomal doxorubicin 63 splice variants 63 antitumor 63 CINTREDEKIN BESUDOTOX 63 epigenetic therapies 63 #I TM# 63 midkine 63 JAK2 inhibitors 63 anticancer activity 63 MGCD# [001] 63 lumiliximab 63 Curaxin 63 RAV# 63 antiangiogenic agents 63 axitinib 63 bispecific antibody 63 JAK1 63 immatics 63 secretory phospholipase A2 sPLA2 63 CD# antibody [001] 63 CoFactor 63 hA# 63 pharmacodynamic PD 63 PEP# [003] 63 vorinostat 63 LEX System 63 preclinical efficacy 63 NEUGENE R 63 NeuVax 63 inecalcitol 63 Removab 63 antiangiogenic 63 DOS# 63 midstage trials 63 HuMax EGFr 63 Phase 2a trial 63 AVN# [001] 63 BrachySil TM 63 Proxinium TM 63 immune modulatory 63 stable nucleic acid 63 monoclonal antibody mAb 63 Genasense ® oblimersen 63 doxorubicin Transdrug ® 63 Phase Ib clinical 63 PI3K inhibitor 63 Omacetaxine 63 LNP formulations 63 phosphate S1P 63 trodusquemine 63 oxidative stress inducer 63 EGF receptor 63 TNFa 63 adipiplon 63 small molecule defensin 63 Gleevec resistant 63 ocular formulation 63 seliciclib 63 MEK inhibitor RDEA# 63 Phase 1a clinical 63 chemotherapeutics 63 Anavex #-# 63 targeted radiotherapeutic 63 antisense oligonucleotides 63 PLK1 SNALP 63 Anticalin ® 63 NEUGENE antisense 63 Pertuzumab 63 adecatumumab 62 therapeutically relevant 62 EGFR HER 62 LEP ETU 62 inhibit angiogenesis 62 NP2 62 peptide antigens 62 pharmacodynamic properties 62 APOPTONE 62 IAP inhibitor 62 humanized antibodies 62 Alocrest 62 AS# amonafide L malate 62 DAVANAT R 62 phase IIb clinical 62 Toraymyxin TM 62 radezolid 62 humanized anti 62 CXCR4 receptor 62 diagnostic biomarker 62 HIF 1α 62 Apoptone 62 cannabinor 62 RGB # 62 #D#C# 62 histone deacetylase HDAC 62 Aurora kinase inhibitor 62 immunotherapeutics 62 selective inhibition 62 IMP# 62 histone deacetylase HDAC inhibitor 62 immunological diseases 62 HCV protease 62 Virulizin R 62 polymerase inhibitors 62 Factor VIIa 62 heparanase 62 EOquin 62 immunotoxins 62 optimal dosing regimens 62 metabolite identification 62 IND submission 62 CD# expressing 62 gastrin 62 CD# CEA 62 TG# [003] 62 phase IIa clinical 62 Hsp# inhibition 62 PI3K delta 62 antitumor efficacy 62 TRV# [001] 62 redox active 62 torezolid 62 HuMax CD# 62 anti amnesic 62 nalbuphine ER 62 NGX# 62 Urocidin 62 vinca alkaloid 62 bortezomib Velcade 62 Fleximer 62 delafloxacin 62 antitumor activity 62 ALN RSV# 62 highly selective inhibitor 62 UPLYSO 62 PET tracers 62 tramiprosate Alzhemed TM 62 radiolabeled TM# 62 ANAVEX #-# [001] 62 BRAF inhibitor 62 orally administered inhibitor 62 ongoing Phase 1b 62 therapeutic peptide 62 proteasome inhibitor 62 antiangiogenesis 62 antitumor effect 62 HCV protease inhibitors 62 TKM ApoB 62 lipid particle 62 UsiRNAs 62 personalized immunotherapy 62 IAP inhibitors 62 CG# [003] 62 selective modulator 62 Cloretazine 62 Neuradiab 62 Cloretazine R 62 Chemophase 62 Phase Ib II 62 MyVax R 62 Nanobodies 62 Ramoplanin 62 riociguat 62 retapamulin 62 Poly ICLC 62 gamma secretase inhibitor 62 trastuzumab Herceptin 62 INT# [002] 62 induce apoptosis 62 pan HDAC inhibitor 62 immunomodulation 62 galectin 3 62 Trofex 62 metaglidasen 62 Zysolin TM 62 TOCOSOL Paclitaxel 62 multitargeted 62 durable remissions 62 IMC #B 62 MUC1 62 imetelstat 62 R#/MEM # 62 isatoribine 62 endostatin 62 cleavable linker 62 VitiGam 62 xenograft models 62 farletuzumab 62 nanomolar 62 PEGylated 62 Phase 2a clinical trials 62 lytic 62 ruxolitinib 62 P2V TM 62 selective inhibitors 62 Anticalin 62 imexon 62 anti angiogenic agent 62 intranasal delivery 62 HyACT 62 elotuzumab 62 epothilone 62 Enzastaurin 62 tolerogenic 62 tezampanel NGX# 62 TACI Ig 62 incyclinide 62 anti CD# antibodies 62 demonstrated antitumor activity 62 ONCONASE R 62 trastuzumab emtansine T DM1 62 CA9 SCAN 62 therapeutic regimens 62 Phase IIb clinical trials 62 optimal dosing 62 glucagon receptor 62 DCVax R 62 PRT# 62 Azedra TM 62 angiogenesis inhibitor 62 potency selectivity 62 mda 7 62 MEK inhibitor 62 JVRS 62 mimetics 62 CD# monoclonal antibody 62 HuMax CD4 62 p# inhibitor 62 pharmacokinetic PK 62 Aplidin R 62 aleglitazar 62 dacetuzumab 62 IL# PE#QQR 62 Vidaza azacitidine 62 tumorigenicity 62 Proellex TM 62 Ampligen ® 62 mesothelin 62 HAAH 62 potently inhibit 62 humanized monoclonal antibodies 62 entinostat 62 induces apoptosis 62 biodistribution 62 oncolytic 62 huN# DM1 62 EGFR HER2 62 belinostat 62 receptor inhibitor 62 recombinant antibodies 62 iSONEP 61 KNS # 61 Preclinical studies 61 Litx 61 cetuximab Erbitux 61 DNA intercalator 61 AAV vector 61 elvucitabine 61 methylation markers 61 protein kinase inhibitor 61 defensin mimetic antibiotic 61 Davanat 61 potent antitumor activity 61 THR beta agonist 61 IGF IR 61 generation purine nucleoside 61 XL# inhibits 61 TKM PLK1 61 mimetic compounds 61 bactericidal activity 61 paclitaxel Taxol ® 61 Phase #b/#a 61 glycosylated 61 Quinamed 61 anticancer agent 61 tafamidis 61 SNALP technology 61 mRNA antagonists 61 mouse xenograft models 61 ProSavin 61 oxysterols 61 non nucleoside inhibitor 61 Trp p8 61 radiolabeled monoclonal antibody 61 OncoGel 61 cyclophilin inhibitor 61 LB# [003] 61 OGeS 61 rhIGFBP 3 61 Allovectin 7 61 cytotoxic 61 PEGPH# 61 Thiovir 61 anti proliferative 61 Aurora kinase inhibitors 61 anti CD3 61 Pimavanserin 61 intranasal formulation 61 SRT# [003] 61 trastuzumab DM1 61 lesinurad 61 tkRNAi 61 ospemifene 61 DFMO 61 neratinib 61 Src inhibitors 61 DCCR 61 HDACi 61 galiximab 61 chemotherapeutic drug 61 ETBs 61 ToGA 61 Pralatrexate 61 tumor specific antigen 61 Telintra 61 GLPG# 61 Homspera 61 AeroLEF TM 61 NSCLC tumors 61 mTOR inhibitors 61 PNP inhibitor 61 fosbretabulin 61 LSI #P 61 nicotinic alpha 7 61 Viramidine 61 pharmacodynamic biomarkers 61 Triapine R 61 DepoVax ™ 61 aurora kinase 61 selective kinase inhibitor 61 novel orally bioavailable 61 AMD# [003] 61 faropenem 61 MORAb 61 Intravenous CP 61 torezolid phosphate 61 ixabepilone 61 telomerase inhibitor 61 vitro cytotoxicity 61 GFT# 61 Thiarabine 61 vitro experiments 61 NEUMUNE 61 ANAVEX #-# [003] 61 MDV# 61 cediranib 61 SERCA2a 61 Zolinza 61 Fodosine 61 MAb 61 Ceplene/IL-2 61 Kahalalide F 61 talactoferrin 61 thrombopoietin 61 HGS ETR1 mapatumumab 61 EpCAM 61 Solazed TM 61 lentiviral 61 Elagolix 61 Aurexis 61 fusion proteins 61 TLR9 agonist 61 mechanistic insights 61 evaluating tivozanib 61 Celator 61 CCR5 mAb 61 Alzhemed TM 61 Hsp# inhibitors 61 epithelial tumors 61 replicon 61 Aflibercept 61 L BLP# 61 PSP# [002] 61 ganaxolone 61 Immunotherapeutic 61 picomolar 61 gemcitabine Gemzar ® 61 PDX pralatrexate 61 antisense drug 61 interferon lambda 61 GAMMAGARD 61 registrational 61 chemokine receptor 61 multicenter Phase II 61 nucleoside analogs 61 SCIB1 61 biologic therapeutics 61 Listeria vaccine 61 immunotoxin 61 refractory chronic lymphocytic 61 RNAi therapeutic targeting 61 GALNS 61 TAFA# 61 targets Galectin receptors 61 XmAb 61 AMN# [001] 61 thalidomide Thalomid 61 Vandetanib 61 Civacir 61 pharmacokinetic parameters 61 vivo efficacy 61 VAPRISOL 61 Phase Ib clinical trials 61 mitogen activated ERK kinase 61 Romidepsin 61 TOCOSOL Camptothecin 61 BiTE antibody 61 nucleoside analog 61 CobaCyte 61 plasmid DNA vaccine 61 oral bioavailability 61 ALN TTR 61 AEGR 61 CytoFabTM 61 Angiocept 61 humanised antibody 61 novel VDA molecule 61 OvaRex ® MAb 61 trastuzumab Herceptin ® 61 Phase IIb trials 61 Dextofisopam 61 Kevetrin 61 Nanobodies ® 61 otelixizumab 61 ANG# 61 TTR gene 61 LungExpress Dx TM 61 EGEN 61 proprietary polysaccharide 61 NP2 Enkephalin 61 K ras mutations 61 Vaxfectin TM 61 atacicept 61 resolvin 61 HQK 61 ISTODAX 61 tolevamer 61 ALK inhibitors 61 EP #R 61 tremelimumab 61 delipidation 61 skeletal muscle contractility 61 anti angiogenic agents 61 Reverset 61 Lenocta 61 lentiviral vectors 61 BCX# 61 Carfilzomib 61 FluCide 61 Velcade bortezomib 61 phase IIb trial 61 TBC# 61 retaspimycin 61 ATL# [002] 61 microtubule inhibitor 61 MLN# 61 alpha fetoprotein AFP 61 Technosphere Insulin 61 potently inhibited 61 PRTX 61 LY# [003] 61 pharmacokinetic studies 61 doxorubicin Transdrug R 61 Xcellerated T Cells 61 Triolex 61 lucinactant 61 antisense drugs 61 BRAF mutation 61 veltuzumab 61 TRO# 61 Cintredekin Besudotox 61 AAG geldanamycin analog 61 racemic baclofen 61 Orally administered 61 Linjeta TM 61 efaproxiral 61 BN# [002] 61 MNTX 60 FK# 60 Asentar 60 PROCHYMAL 60 Marqibo 60 Exelixis compounds 60 ELND# 60 Lixivaptan 60 ALK inhibitor 60 MetAP2 60 FLT3 60 Scancell 60 ApoB SNALP 60 Tarceva TM 60 RLY# 60 P#X# 60 preclinical toxicology 60 EOquin TM 60 Neuvenge 60 CYT# 60 mutated BRAF gene 60 Chemokine 60 Alferon N 60 cytostatic 60 bortezomib Velcade ® 60 Sphingomab 60 Menerba 60 immune stimulatory 60 Azedra ™ 60 HCV protease inhibitor 60 Guanilib 60 2 methoxyestradiol 60 Epigenomics proprietary 60 alagebrium 60 ONCONASE 60 oral gallium 60 Anticalins R 60 DermaVir Patch 60 cytotoxicity 60 CDK inhibitors 60 osteogenic 60 Onalta ™ 60 Hedgehog inhibitor 60 crizotinib PF # 60 tumor antigen 60 ALN TTR# 60 plasma kallikrein inhibitor 60 DepoVax 60 seliciclib CYC# 60 HSP# inhibitors 60 Cobalamin 60 MyVax ® 60 mecamylamine 60 Bortezomib 60 IL #p# 60 DermaVir 60 enzyme inhibitor 60 pharmacokinetic interactions 60 anti angiogenic drugs 60 myeloma cells 60 ARIKACE 60 motesanib 60 SinuNase ™ 60 CRLX# 60 Cytolin R 60 Phase Ib 60 Lpathomab 60 rNAPc2 60 cell lysate 60 nanomedicines 60 Hsp# inhibitor 60 SIR Spheres 60 rifalazil 60 ISF# 60 nucleoside reverse transcriptase inhibitor 60 EGS# 60 tramiprosate 60 Atiprimod 60 Cerashield 60 calcitonin 60 DNA plasmids 60 TG# [001] 60 systemic RNAi therapeutic 60 IIa trial 60 liposome formulations 60 PI3K Akt 60 Solorel TM 60 tesetaxel 60 muscarinic 60 CCR1 60 volociximab 60 WT1 60 viral kinetics 60 PSN# [001] 60 DiLA2 liposomes 60 Azixa 60 Aeroquin 60 BiTE antibodies 60 nanomolar range 60 PKM2 60 Vicinium TM 60 DAVANAT ® 60 hedgehog pathway 60 brivaracetam 60 human hepatocytes 60 pradefovir 60 vitro studies 60 daptomycin 60 Nexavar sorafenib 60 oral JAK1 60 murine monoclonal antibody 60 small molecule inhibitors 60 ATL/TV# 60 pralatrexate 60 MVA BN R 60 c MYC 60 oral salmon calcitonin 60 Allovectin 7 R 60 NADiA 60 Reports Preclinical Data 60 pediatric acute lymphoblastic 60 SIRT1 activators 60 parthenolide 60 apoptosis inducing 60 Bendavia 60 ThermoDox R 60 antisense inhibition 60 OvaRex MAb 60 sapacitabine 60 inhibit metastasis 60 Spiegelmer ® 60 Perifosine 60 anti fibrotic 60 Annamycin 60 Cyclin E 60 inhibitory effects 60 antibody fragment 60 OxBC 60 targeting PCSK9 60 Phase #/#a trial 60 EndoTAG 60 RhuDex ® 60 #HT#A 60 DR Cysteamine 60 inhibitor RG# 60 TLR antagonists 60 PLX# 60 Interferon alpha 60 Intarcia 60 omacetaxine mepesuccinate 60 T#I [002] 60 oral taxane 60 lipid particles 60 NexACT 60 anticancer compounds 60 GSK3B 60 p# inhibitors 60 velaglucerase alfa 60 inhibiting angiogenesis 60 polysaccharide polymer 60 sirtuin inhibitors 60 IRX 2 60 Affibody ® molecules 60 NeoLipid TM 60 IL #E 60 Sapacitabine 60 Capesaris 60 immunomodulating 60 Onalta 60 promoter methylation 60 VA# [002] 60 novel histone deacetylase 60 anticancer agents 60 eIF 4E 60 Xinlay 60 potent inhibition 60 BMS# 60 malignant ascites 60 oral Xeloda 60 Elocalcitol 60 ThermoDox ® clinical 60 genetic biomarkers 60 throughput RNAi 60 EP1 receptor 60 signal transduction inhibitor 60 luteinizing hormone releasing 60 GelSite polymer 60 isotype 60 plasma pharmacokinetics 60 potent cytotoxic 60 LHRH 60 BLA filing 60 sulfonylhydrazine class 60 ulimorelin 60 Th2 cytokines 60 selective agonist 60 cytotoxin 60 Multimeric 60 DsiRNA 60 GVAX ® 60 BAY #-# 60 Taxotere chemotherapy 60 SNT MC# 60 PHX# 60 DiLA2 60 RNAi therapeutic targeting PCSK9 60 SGLT Inhibitors 60 rhIL 7 60 cellular immunotherapy 60 Vitaxin 60 Traficet EN 60 eprotirome 60 Zalypsis 60 DXL TM 60 Vidofludimus 60 phase Ib 60 OMNARIS HFA 60 novel immunomodulatory 60 carbohydrate polymer 60 multiplex assay 60 Phase 1b clinical trials 60 methylnaltrexone 60 P selectin 60 OMP #R# 60 Etubics 60 Aclidinium 60 anticancer therapies 60 Phase 1b trial 60 Apo AI Milano 60 triphosphate 60 Provecta 60 sd rxRNA 60 potent anti angiogenic 60 Saforis 60 Radezolid 60 monoclonal antibody therapies 60 TAp# 60 TLR7 60 SARMs 60 Chemokine Therapeutics 60 LT NS# 60 phase IIa 60 TAT# 60 flavopiridol 60 Protein Kinase C 60 RayBiotech 60 ibudilast 60 Combidex 60 effector function 60 vitro ADME 60 cilengitide 60 shRNA libraries 60 predictive biomarkers 60 delta isoform 60 integrin receptors 60 FM VP4 60 Maximum Tolerated Dose MTD 60 MyVax 60 human microdosing 60 KineMed 60 HTS assay 60 Doxorubicin 60 nucleoside 60 Tumour Vascular Disrupting Agent 60 atrasentan 60 somatostatin receptors 60 Anthim 60 DCVax ® 60 PARP inhibition 60 vosaroxin 60 AZILECT ® 60 MAXY G# 59 sorafenib Nexavar 59 GVAX 59 adrenergic regulation 59 Excellagen 59 antitumoral